Replicor to disclose interim REP 2139 clinical efficacy data in patients with chronic hepatitis B at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012).
15-19 February 2012, Taiwan International Convention Center, Taipei, Taiwan.
February 17th, 2012 – Replicor will disclose updated interim results from its proof of concept clinical trial of its second clinical candidate, REP 2139 for the treatment of chronic hepatitis B at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012) currently being held from 15-19th of February. This is the largest annual meeting in South Asia dedicated to treatment of liver disease which typically attracts thousands of physicians and researchers. This trial is examining the safety and efficacy of REP 2139 in human patients with chronic hepatitis B (HBV).
REP 2139 represents the latest clinical candidate in a new class of antiviral agent that blocks the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. The previous clinical candidate, REP 2055, rapidly cleared serum HBsAg in patients infected with HBV and allowed many of these patients to regain effective immunological control over their infection, resulting in sustained virologic responses after only 5-6 months of treatment. Replicor will present updated clinical efficacy results from a new cohort of patients currently being treated with REP 2139 in an oral presentation on Feb 17th, 2012.
The 22nd Conference of the Asian Pacific Association for the Study of the Liver.